FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210627733> ?p ?o ?g. }

• W3210627733 endingPage "205" @default.
• W3210627733 startingPage "199" @default.
• W3210627733 abstract "Breast cancer incidence increases with age and real-world data is essential to guide prescribing practices in the older population. The aim of this study was to collect large scale real-world data on tolerability and efficacy of palbociclib + AI in the first line treatment of ER+/HER2-advanced breast cancer in those aged ≥75 years.14 cancer centres participated in this national UK retrospective study. Patients aged ≥75 years treated with palbociclib + AI in the first line setting were identified. Data included baseline demographics, disease characteristics, toxicities, dose reductions and delays, treatment response and survival data. Multivariable Cox regression was used to assess independent predictors of PFS, OS and toxicities.276 patients met the eligibility criteria. The incidence of febrile neutropenia was low (2.2%). The clinical benefit rate was 87%. 50.7% of patients had dose reductions and 59.3% had dose delays. The 12- and 24- month PFS rates were 75.9% and 64.9%, respectively. The 12- and 24- month OS rates were 85.1% and 74.0%, respectively. Multivariable analysis identified PS, Age-adjusted Charlson Comorbidity Index (ACCI) and number of metastatic sites to be independent predictors of PFS. Dose reductions and delays were not associated with adverse survival outcomes. Baseline ACCI was an independent predictor of development and severity of neutropenia.Palbociclib is an effective therapy in the real-world older population and is well-tolerated with low levels of clinically significant toxicities. The use of geriatric and frailty assessments can help guide decision making in these patients." @default.
• W3210627733 created "2021-11-08" @default.
• W3210627733 creator A5000163264 @default.
• W3210627733 creator A5001814594 @default.
• W3210627733 creator A5003689289 @default.
• W3210627733 creator A5004233634 @default.
• W3210627733 creator A5005834192 @default.
• W3210627733 creator A5008140774 @default.
• W3210627733 creator A5011969138 @default.
• W3210627733 creator A5016184299 @default.
• W3210627733 creator A5017015026 @default.
• W3210627733 creator A5021339122 @default.
• W3210627733 creator A5022190021 @default.
• W3210627733 creator A5026520424 @default.
• W3210627733 creator A5026610336 @default.
• W3210627733 creator A5034290416 @default.
• W3210627733 creator A5056496239 @default.
• W3210627733 creator A5058992352 @default.
• W3210627733 creator A5062516612 @default.
• W3210627733 creator A5064639261 @default.
• W3210627733 creator A5069632911 @default.
• W3210627733 creator A5079560617 @default.
• W3210627733 creator A5084650683 @default.
• W3210627733 date "2021-12-01" @default.
• W3210627733 modified "2023-10-06" @default.
• W3210627733 title "Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study" @default.
• W3210627733 cites W2000445173 @default.
• W3210627733 cites W2034666844 @default.
• W3210627733 cites W2079633011 @default.
• W3210627733 cites W2094599068 @default.
• W3210627733 cites W2106114209 @default.
• W3210627733 cites W2120729896 @default.
• W3210627733 cites W2128412585 @default.
• W3210627733 cites W2148345265 @default.
• W3210627733 cites W2167600867 @default.
• W3210627733 cites W2552099557 @default.
• W3210627733 cites W2883737490 @default.
• W3210627733 cites W2901884329 @default.
• W3210627733 cites W2920014560 @default.
• W3210627733 cites W2975749949 @default.
• W3210627733 cites W3121771782 @default.
• W3210627733 cites W3145417893 @default.
• W3210627733 cites W3172073204 @default.
• W3210627733 doi "https://doi.org/10.1016/j.breast.2021.10.010" @default.
• W3210627733 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8569699" @default.
• W3210627733 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34736090" @default.
• W3210627733 hasPublicationYear "2021" @default.
• W3210627733 type Work @default.
• W3210627733 sameAs 3210627733 @default.
• W3210627733 citedByCount "6" @default.
• W3210627733 countsByYear W32106277332022 @default.
• W3210627733 countsByYear W32106277332023 @default.
• W3210627733 crossrefType "journal-article" @default.
• W3210627733 hasAuthorship W3210627733A5000163264 @default.
• W3210627733 hasAuthorship W3210627733A5001814594 @default.
• W3210627733 hasAuthorship W3210627733A5003689289 @default.
• W3210627733 hasAuthorship W3210627733A5004233634 @default.
• W3210627733 hasAuthorship W3210627733A5005834192 @default.
• W3210627733 hasAuthorship W3210627733A5008140774 @default.
• W3210627733 hasAuthorship W3210627733A5011969138 @default.
• W3210627733 hasAuthorship W3210627733A5016184299 @default.
• W3210627733 hasAuthorship W3210627733A5017015026 @default.
• W3210627733 hasAuthorship W3210627733A5021339122 @default.
• W3210627733 hasAuthorship W3210627733A5022190021 @default.
• W3210627733 hasAuthorship W3210627733A5026520424 @default.
• W3210627733 hasAuthorship W3210627733A5026610336 @default.
• W3210627733 hasAuthorship W3210627733A5034290416 @default.
• W3210627733 hasAuthorship W3210627733A5056496239 @default.
• W3210627733 hasAuthorship W3210627733A5058992352 @default.
• W3210627733 hasAuthorship W3210627733A5062516612 @default.
• W3210627733 hasAuthorship W3210627733A5064639261 @default.
• W3210627733 hasAuthorship W3210627733A5069632911 @default.
• W3210627733 hasAuthorship W3210627733A5079560617 @default.
• W3210627733 hasAuthorship W3210627733A5084650683 @default.
• W3210627733 hasBestOaLocation W32106277331 @default.
• W3210627733 hasConcept C121608353 @default.
• W3210627733 hasConcept C126322002 @default.
• W3210627733 hasConcept C143998085 @default.
• W3210627733 hasConcept C197934379 @default.
• W3210627733 hasConcept C2775930923 @default.
• W3210627733 hasConcept C2776694085 @default.
• W3210627733 hasConcept C2777063308 @default.
• W3210627733 hasConcept C2778375690 @default.
• W3210627733 hasConcept C2779744173 @default.
• W3210627733 hasConcept C2908647359 @default.
• W3210627733 hasConcept C50382708 @default.
• W3210627733 hasConcept C530470458 @default.
• W3210627733 hasConcept C71924100 @default.
• W3210627733 hasConcept C72563966 @default.
• W3210627733 hasConcept C88879693 @default.
• W3210627733 hasConcept C99454951 @default.
• W3210627733 hasConceptScore W3210627733C121608353 @default.
• W3210627733 hasConceptScore W3210627733C126322002 @default.
• W3210627733 hasConceptScore W3210627733C143998085 @default.
• W3210627733 hasConceptScore W3210627733C197934379 @default.
• W3210627733 hasConceptScore W3210627733C2775930923 @default.
• W3210627733 hasConceptScore W3210627733C2776694085 @default.
• W3210627733 hasConceptScore W3210627733C2777063308 @default.

• next